The primary focus of our group is to design and validate novel biomarker concepts for early cancer detection and precision disease management. We have established a biomarker development pipeline based on glycovariants of various tumor markers and extracellular vesicles.

Our research is in the interface of basic and translational research, combining biomarker discovery, antibody and assay development and clinical validation to address the clinical need for the detection of most common solid cancers.